HealthMore in Health→
Neurocrine’s $2.9 billion Soleno deal adds an approved rare-disease drug
Key Takeaways
- Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion.
- The acquisition adds an approved treatment for a rare disease that causes insatiable hunger.
- The deal reflects continued appetite for de-risked rare-disease assets in biotech M&A.
DE
DT Editorial Team··via statnews.com